|Bid||6.46 x 900|
|Ask||6.49 x 800|
|Day's Range||6.30 - 6.51|
|52 Week Range||3.22 - 7.98|
|Beta (5Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.33|
Representing Iveric Bio today are Glenn Sblendorio, chief executive officer; Pravin Dugel, president; David Carroll, chief financial officer; Dhaval Desai, chief development officer; Abraham Scaria, chief scientific officer; and Keith Westby, chief operating officer. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.
Iveric Bio announced financial and operating results for the quarter ended March 31, 2021 and provided a general business update.
NEW YORK, NY / ACCESSWIRE / May 5, 2021 / IVERIC bio, Inc. (NASDAQ:ISEE) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 8:00 AM Eastern Time.